MAIA Biotechnology (MAIA) vs Medicinova (MNOV)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Medicinova (MNOV) has outperformed MAIA Biotechnology (MAIA) over the past year, gaining 23.6% versus a loss of 29.1%. MAIA Biotechnology is the larger company by market cap ($75.3 million vs $74.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MAIA | MNOV |
|---|---|---|
| Share price | $1.22 | $1.52 |
| Market cap | $75.33M | $74.82M |
| 1-day change | +6.09% | -1.30% |
| YTD return | -20.26% | +16.03% |
| 1-year return | -29.07% | +23.58% |
| 5-year return | — | -60.21% |
| Forward P/E | 1.10 | — |
| EPS (TTM) | $-0.62 | $-0.21 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.19 | $3.90 |
| 52-week low | $0.87 | $1.17 |
| Distance from 52-week high | -61.76% | -61.03% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +883.61% | +442.76% |
| Average volume | 527.89K | 327.41K |
| Shares outstanding | 61.74M | 49.22M |
| Employees | 13 | 6 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MNOV has outperformed MAIA by 52.6 percentage points over the past year.
About MAIA Biotechnology
MAIA stock →MAIA Biotechnology, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the development of targeted immunotherapies for cancer. Its lead product Ateganosine, a telomere-targeting agent currently in clinical development to evaluate its activity in Non-Small Cell Lung Cancer (NSCLC).
Health Care · Biotechnology: Pharmaceutical Preparations · 13 employees
About Medicinova
MNOV stock →MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, and glioblastoma, as well as prevention of acute respiratory distress syndrome.
Health Care · Biotechnology: Pharmaceutical Preparations · 6 employees
MAIA vs MNOV FAQ
Which is bigger, MAIA Biotechnology or Medicinova?
MAIA Biotechnology (MAIA) is larger, with a market capitalization of $75.33M compared with $74.82M for Medicinova (MNOV).
Which stock has performed better over the past year, MAIA or MNOV?
MNOV returned +23.58% over the past 12 months, compared with -29.07% for MAIA (price return, excluding dividends). Past performance does not predict future results.
Are MAIA Biotechnology and Medicinova in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.